{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-016410","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.650772+00:00","generated_at":"2026-05-16T02:20:38.820209+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Glaukos Q4 record sales $143.1M (+36% YoY); reaffirms FY2026 guidance $600-620M","bullets":["Q4 net sales $143.1M (record), +36% YoY; full year $507.4M, +32% YoY.","GAAP net loss $133.7M ($2.32/sh) includes $112.9M non-cash impairment on Avedro intangible.","Non-GAAP net loss improved to $16.4M ($0.28/sh) from $22.2M ($0.40) in Q4 2024.","U.S. Glaucoma sales record $86.4M, +53% YoY; strong growth from iDose TR.","Ended Q4 with $282.6M cash, no debt; 2026 revenue guidance reaffirmed at $600-620M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-016410","json":"https://secwatch.observer/filing/0001104659-26-016410.json","markdown":"https://secwatch.observer/filing/0001104659-26-016410.md","text":"https://secwatch.observer/filing/0001104659-26-016410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000110465926016410/0001104659-26-016410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000110465926016410/gkos-20260217x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:20:38.820209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}